Humacyte, Inc. (NASDAQ:HUMA) Shares Purchased by ARS Investment Partners LLC

ARS Investment Partners LLC lifted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA) by 17.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 99,419 shares of the company’s stock after purchasing an additional 15,000 shares during the quarter. ARS Investment Partners LLC’s holdings in Humacyte were worth $502,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. Brookstone Capital Management purchased a new position in shares of Humacyte during the fourth quarter worth approximately $56,000. Concurrent Investment Advisors LLC purchased a new position in shares of Humacyte in the third quarter valued at $75,000. FORA Capital LLC purchased a new position in shares of Humacyte in the third quarter valued at $96,000. Insigneo Advisory Services LLC acquired a new position in Humacyte in the 3rd quarter valued at about $109,000. Finally, Profund Advisors LLC acquired a new position in Humacyte in the 2nd quarter valued at about $97,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the sale, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. This represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,500,000 shares of company stock worth $6,606,799. Company insiders own 11.20% of the company’s stock.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $4.41 on Tuesday. The company has a market capitalization of $555.04 million, a price-to-earnings ratio of -3.29 and a beta of 1.32. The firm’s 50 day simple moving average is $4.55 and its 200 day simple moving average is $5.65. Humacyte, Inc. has a fifty-two week low of $2.53 and a fifty-two week high of $9.97.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. TD Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Piper Sandler set a $6.00 price target on Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Monday, January 13th. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, Benchmark raised their target price on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, December 23rd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Humacyte has a consensus rating of “Buy” and a consensus target price of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.